CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices. Originally established in 2014 as Brain Stethoscope, Inc., the company underwent a name change to CeriBell, Inc. in August 2015. Its headquarters are located in Sunnyvale, California.
| Metric | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Revenue | $65.44M | $45.23M | $25.92M |
| Cost of Revenue | $8.69M | $7.06M | $4.43M |
| Gross Profit | $56.75M | $38.16M | $21.49M |
| Gross Margin | 86.72% | 84.38% | 82.91% |
| Operating Expenses | $96.46M | $68.20M | $57.51M |
| Operating Income | $-39.71M | $-30.04M | $-36.02M |
| Operating Margin | -60.68% | -66.43% | -138.96% |
| Net Income | $-40.45M | $-29.46M | $-37.16M |
| Net Margin | -61.82% | -65.15% | -143.37% |
| EPS (Basic) | $-3.39 | $-1.26 | $-1.59 |
| EBITDA | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A |